The lower NT-proBNP levels in the empagliflozingroup together with functional (LV-EF, diastolic function) and structural (LVESV,LVEDV) benefits, the EMMY trial provides evidence for a clinical benefit ofSGLT2-inhibitors in patients suffering from MI. The gene discussed is NPPB; the disease is myocardial infarction.